Patents Examined by Yevgeny Valenrod
  • Patent number: 11225452
    Abstract: The present disclosure provides regioselective methods for synthesizing intermediates useful in making prostacyclin. The methods include heating the compound of Formula 2 at a temperature of 180° C. to 185° C. Wherein the heating comprises irradiating the compound of formula 2 with microwave radiation.
    Type: Grant
    Filed: August 12, 2020
    Date of Patent: January 18, 2022
    Assignee: United Therapeutics Corporation
    Inventors: Hitesh Batra, Sudersan M. Tuladhar, David A. Walsh
  • Patent number: 11207308
    Abstract: This invention relates to novel pharmaceutical compositions comprising a therapeutically effective combination of a dopaminergic stabilizer known as Pridopidine, and an inhibitor of the vesicular monoamine transporter type 2 (VMAT) known as Tetrabenazine. The pharmaceutical compositions for use according to the invention are contemplated particularly useful for improving the symptomatic therapeutic effects, and for reducing the adverse effects, of Tetrabenazine in the treatment of movement disorders, and in articular movement disorders associated with Huntington's disease, Gilles de la Tourette's syndrome, or tardive dyskinesia.
    Type: Grant
    Filed: November 28, 2018
    Date of Patent: December 28, 2021
    Assignee: PRILENIA NEUROTHERAPEUTICS LTD.
    Inventors: Ross Nicholas Waters, Eva Susanna Holm Waters
  • Patent number: 11208372
    Abstract: Disclosed are compounds of formula (I) (R1OOC)a—R2(OH)c—COO—(CnH2n—O)m—OC—R3(OH)d—(COOR4)b??(I) wherein R1 and R4 independently of one another are hydrogen, a metal cation, an ammonium cation, C1-C6-alkyl, cycloalkyl with three to nine ring carbon atoms, aryl with five to ten ring carbon atoms, aryl that is substituted with one or two alkyl groups, aryl that is connected via an alkylene group with the carboxyl group, —(CnH2n—O)m—H or —O—R2(COOR1)a+1, R2 and R3 independently of one another are aliphatic hydrocarbon residues with one to eight carbon atoms, a and b independently of one another are integers from 1 to 4, c is an integer from 0 to 4, d is an integer from 1 to 4, n is 2, 3 or 4, and m is 1, 2, 3 or 4, with the proviso that R1 and R4 may be different within a molecule within the given definitions. These compounds are characterized by a very good complexation power for metal cations and can be used in detergents and cleaning agents, in oil extraction and for water softening.
    Type: Grant
    Filed: August 11, 2020
    Date of Patent: December 28, 2021
    Assignee: WEYLCHEM PERFORMANCE PRODUCTS, GMBH
    Inventors: Roman Morschhäuser, Said Kchirid, Judith Preuschen, Bo Kuhse
  • Patent number: 11202787
    Abstract: This invention provides new methods for a) identifying Cushing's Syndrome patients at high risk of developing hypokalemia during glucocorticoid receptor modulator (GRM) treatment, and b) for prophylactically treating such patients to prevent, or reduce the severity of, hypokalemia. Patients at such high risk may be identified prior to their developing hypokalemia. Such a patient may be an adult patient with endogenous Cushing's Syndrome having type 2 diabetes mellitus or glucose intolerance to control hyperglycemia secondary to hypercortisolism. Patients may be identified by an above-threshold level of ACTH or cortisol in a patient sample taken post-GRM administration or pre-GRM administration, respectively. Upon identifying such a patient prior to the development of low potassium, the present methods provide for prophylactically treating the patient by administration of one or more hypokalemia treatments concurrently with an increased dose of GRM or with an initial dose of GRM to prevent hypokalemia.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: December 21, 2021
    Assignee: Corcept Therapeutics, Inc.
    Inventor: Andreas Moraitis
  • Patent number: 11202779
    Abstract: The present invention provides compositions and methods for the treatment of neoplasms, in particular, by targeting of quiescent cancer cells with therapeutic agents in combination with other treatments effective against certain neoplastic conditions, in particular, anti-cancer treatment with EGFR inhibitor agents.
    Type: Grant
    Filed: June 17, 2019
    Date of Patent: December 21, 2021
    Assignee: Felicitex Therapeutics, Inc.
    Inventors: Maria Vilenchik, Michael Frid, Alexandra Kuznetsova, Yuriy Gankin, Marc Duey
  • Patent number: 11197863
    Abstract: Disclosed are methods and compositions for treating pediatric embryonal tumors. The methods and compositions utilize or include an inhibitor of polo-like kinase 4 (PLK4) for treating pediatric embryonal tumors.
    Type: Grant
    Filed: August 29, 2018
    Date of Patent: December 14, 2021
    Assignee: ANN AND ROBERT H. LURIE CHILDREN'S HOSPITAL OF CHICAGO
    Inventors: Simone T. Sredni, Tadanori Tomita
  • Patent number: 11197839
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: March 4, 2021
    Date of Patent: December 14, 2021
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 11197862
    Abstract: Methods for reducing platinum drug-induced toxicity in a cell expressing Organic Cation Transporter 2 (OCT2), methods for reducing platinum drug-induced toxicity in a subject, methods for treating cancer, methods for increasing efficacy of platinum drug treatment in a subject, and pharmaceutical compositions are described. The described methods and compositions include an OCT2 inhibitor where the OCT2 inhibitor is buflomedil or a salt thereof, dolutegravir or a salt thereof contains an imidazole, or is miconazole or a salt thereof.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: December 14, 2021
    Assignee: XOMICS BIOPHARMA, INC.
    Inventors: Yong Huang, Dominique P. Bridon, Xuexiang Zhang, Chien-Ming Li
  • Patent number: 11191739
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: March 4, 2021
    Date of Patent: December 7, 2021
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 11192836
    Abstract: Provided is a method for producing a fluorine-containing organic compound. The method can immediately detect the occurrence of a side reaction in direct fluorination reaction using fluorine gas and can give a highly pure fluorine-containing organic compound at a high yield. A raw material liquid (1) containing a raw material organic compound having a hydrogen atom and two or more carbon atoms is reacted with fluorine gas in a reaction container (11) to replace the hydrogen atom of the raw material organic compound with a fluorine atom to give a fluorine-containing organic compound. In the reaction, tetrafluoromethane contained in a gas phase (2) in the reaction container (11) is continuously measured, and the amount of the fluorine gas supplied to the reaction container (11) is controlled depending on the measured value of the tetrafluoromethane.
    Type: Grant
    Filed: November 7, 2018
    Date of Patent: December 7, 2021
    Assignee: SHOWA DENKO K.K.
    Inventors: Yohsuke Fukuchi, Shinichi Yorozuya, Nozomi Kusumoto, Hiroshi Kobayashi
  • Patent number: 11185528
    Abstract: Methods of treating or preventing allergic or pulmonary diseases characterized by endothelial dysfunction with Alda-1 are presented. Treatment of pulmonary endothelial cells subjected to hyperoxia with Alda-1 showed an increase in ALDH2 activity and expression. Treatment with Alda-1 also illustrated a decrease in oxidative stress, a decrease in reactive oxygen species (ROS), a decrease in apoptosis, a decrease in inflammation and an enhancement of mitochondrial membrane potential.
    Type: Grant
    Filed: April 3, 2020
    Date of Patent: November 30, 2021
    Assignee: University of South Florida
    Inventors: Narasaiah Kolliputi, Richard F. Lockey, Lakshmi Galam
  • Patent number: 11186796
    Abstract: A liquid anti-friction composition includes an ester product having a number average molecular weight that is greater than 3800 g/mol, and obtained by subjecting a mixture that includes diglycerol, a monobasic acid component, and a dibasic acid component to an esterification reaction. The monobasic acid component includes at least one C14-C24 branched chain fatty acid.
    Type: Grant
    Filed: July 7, 2020
    Date of Patent: November 30, 2021
    Assignee: PATECH FINE CHEMICALS CO., LTD.
    Inventors: Wei-Chieh Liang, Jung-Tsung Hung, Hsu-Hua Tang, Jun-Wei Wu, Jeng-Shiang Tsaih
  • Patent number: 11185553
    Abstract: The present invention relates to a composition for preventing, treating, or alleviating ischemia-reperfusion injury, containing bile acid. According to the present invention, bile acid increases intranuclear beta-catenin levels, interferes with the opening of a mitochondria permeable transition pore (mPTP), and has excellent effects, in ischemia-reperfusion injury animal models, of alleviating tissue injury and reducing the size of infarcts, thereby being usable in the prevention, treatment, or alleviation of ischemia-reperfusion injury.
    Type: Grant
    Filed: October 31, 2017
    Date of Patent: November 30, 2021
    Assignee: SAMSUNG LIFE PUBLIC WELFARE FOUNDATION
    Inventors: Hyeon Cheol Gwon, Hyung Suk Jang
  • Patent number: 11168053
    Abstract: Compositions comprising a sulfonated reaction product or a salt thereof may be prepared from a biphenyl compound that has been alkylated with an olefin of formula R1R2CCH2, wherein R1 is a C6-C24 hydrocarbyl group, and R2 is H or a C6-C24 hydrocarbyl group. Methods for sulfonating an alkylated biphenyl compound prepared from a biphenyl compound that has been alkylated with an olefin of formula R1R2CCH2, wherein R1 is a C6-C24 hydrocarbyl group, and R2 is H or a C6-C24 hydrocarbyl group may comprise contacting the alkylated biphenyl compound with a sulfonating reagent; forming a sulfonated reaction product; and converting the sulfonated reaction product into a sulfonate salt.
    Type: Grant
    Filed: August 18, 2020
    Date of Patent: November 9, 2021
    Assignee: ExxonMobil Chemical Patents Inc.
    Inventors: Abhimanyu O. Patil, Satish Bodige, Arben Jusufi, Shane Deighton, Kanmi Mao, Alan A. Galuska
  • Patent number: 11168048
    Abstract: Alkoxylated hydroxycarboxylic acids according to a formula I? are provided herein, as well as uses thereof and a process for production thereof. Compound 2-[2-(2-hydroxyethoxy)ethoxy]propanoic acid being exclude.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: November 9, 2021
    Assignee: BASF SE
    Inventors: Sophia Ebert, Roman Benedikt Raether
  • Patent number: 11147781
    Abstract: Disclosed herein are methods and compositions for alleviating side effects of statin administration, such as myopathic or myalgic side effects, short-term memory loss, abnormal liver function, glucose intolerance, hyperglycemia, increased risk for diabetes, or cumulative trauma disorder, comprising administration of ?-hydroxy ?-methylbutyrate (HMB) to an individual taking a statin. Also disclosed are methods and compositions for alleviating acute rhabdomyolysis comprising administration of HMB. The disclosure further provides uses of HMB in combination with a statin to alleviate side effects of statin administration.
    Type: Grant
    Filed: February 12, 2019
    Date of Patent: October 19, 2021
    Inventor: Roland W. Winterfield
  • Patent number: 11147814
    Abstract: The invention provides a salt of a tetrahydropyranylmethylaminopyrimidine amide, such as the citrate salt of (4-((3R,4R)-3-methoxytetrahydropyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2R,6S)-6-(p-tolyl)tetrahydro-2H-pyran-2-yl)methylamino)pyrimidin-4-yl)methanone, pharmaceutical compositions containing the same, processes for preparing the same, and methods of medical treatment using the same.
    Type: Grant
    Filed: February 11, 2020
    Date of Patent: October 19, 2021
    Assignee: Centrexion Therapeutics Corporation
    Inventors: Markus Ostermeier, Ulrike Werthmann
  • Patent number: 11135208
    Abstract: Provided herein are pharmaceutical compositions comprising a class of calcium channel blockers and at least one chelating agent. More specifically, the pharmaceutical compositions comprise at least one 1,4-dihydropyridine (DHP) compound and at least one chelating agent. The chelating agents used in this disclosure can decrease the degradation of the constituent DHPs of the DHP compositions. The DHP compositions can be used to treat cardiovascular disorders and are more stable for prolonged periods of time.
    Type: Grant
    Filed: March 11, 2020
    Date of Patent: October 5, 2021
    Assignee: American Regent, Inc.
    Inventors: Daniel Walter Wehrung, Meng Zhong, Saral Pinkal Patel, Bindhu Madhavi Rayaprolu
  • Patent number: 11123292
    Abstract: A pharmacologically acceptable emulsion of biocompatible solvent microdroplets is provided for treating atherosclerosis, heart disease and stroke. Intravenous administration of the biocompatible solvent microdroplets enables the microdroplets to bind and dissolve free cholesterol, cholesterol esters or other fatty compounds within the plaque. A high level of selectivity is ensured from energy principals, by designing the microdroplets to have a low interfacial surface energy when binding to free cholesterol or cholesterol esters in arterial plaque and a high interfacial surface energy when coming into contact with blood cells or endothelial cells along the walls of blood vessels. A review of many compounds which may form the basis of the biocompatible solvent from which the microdroplets are fabricated, as well as their solubility parameters are provided.
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: September 21, 2021
    Inventor: Catherine Beaudin
  • Patent number: 11117859
    Abstract: A compound with anti-drug resistant bacteria activity having the following formula (I) is disclosed. The methods of preparing the compound of formula (I) are also disclosed.
    Type: Grant
    Filed: February 12, 2021
    Date of Patent: September 14, 2021
    Assignee: SHAANXI UNIVERSITY OF SCIENCE AND TECHNOLOGY
    Inventors: Dan Yang, Jingyi Li, Liang Xin, Qianqian Zhao, Liang Qi, Bin Tian, Jian Zha, Wenbo Yao, Gennian Mao, Han Li, Chunyang Shi, Yongbo Wang, Jingwen Xu